We are presenting 17-y old boy with severe aplastic anemia, transplanted with serologically HLA identical sister (18y). Both were CMV+. Conditioning was with HD-Cy (2.5 gm/m 2 , 3d.). GvHD prophylaxis was with CyA/MTX, with CyA and pred. after acute GvHD gr.I (skin) from D+8. Patient was well, with confirmed engraftment (karyotype change) to D+210. He was on CyA (levels Ͼ200 g/L up to D160) and pred. (0.7 mg/kg), with all antiinfective prophylaxis. He had only slight skin changes (mild chr. GvHD) and hypertrichosis. At D200 tapering of CyA and prednisone started (1/3 decrease). He developed typical acute GvHD gr.IV (skin, hut, liver) with diarrhea, vomiting, cramps and hematochesia. Blood count was normal, but there were signs of hepatic lesions. Viral markers were unchanged in two sera samples (HSV, VZV, CMV) and there was no detected CMV in pathological specimens from stomach. He accepted only upper endoscopy and it revealed mucosal erythema but not full blown histological changes of GvHD. He refused other investigations. Initial therapy for GvHD failed (CyA iv, Ͼ300 g/L, pred. 1-2 mg/kg and pulse methylprednisone 1 gm/m 2 od. 7 pulses). Second line therapy was started (CP 1 gm/m 2 1.d, ATG 10 vials for 2 d. and prednisone 2 mg/kg iv, with CyA iv). After initial decrease of diarrheas, soon he developed severe thrombocytopenia and bloody discharge and further deteriorates. Inspite of very fierce therapy he developed intestinal performation and died. Postmortem was refused. Acute GvHD in our patient can occur late in posttransplant course, and we believe that molecular phenotyping is necessary for complete HLA matching. Longer immunosuppression (up to one year since PBSCT) could be beneficial in some patients.
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